| |
Are you thinking about launching a study? Or are you in the middle of managing a biopharma project? Learn more about the major risks surrounding your work and the best ways to manage your project for success. Download the App Note here. 
|
|
Today's Big NewsNov 4, 2022 |
| By James Waldron Galapagos is not a company lacking a vision—in fact, they’ve just made their second strategic announcement in six months. This one comes with a further pipeline trim and the loss of 200 roles. |
|
|
|
By James Waldron In a third-quarter earnings release, the Maryland-based biotech said that it had made the call to end development of the antibody, dubbed NC318, after reviewing data of the drug as monotherapy, including a phase 2 trial that had produced “no responses.” |
By Gabrielle Masson Biomind Labs just hit a landmark on its trip that has clinic flagged as the final destination, posting new data that shows its psychedelic candidate aimed at helping patients with depression is safe and tolerable for healthy individuals. |
Sponsored by Fortress Biotech With 9 marketed products and 20 clinical programs, Fortress Bio’s business model is designed to decrease risk and expense while creating a regular flow of value-creating events for shareholders. |
By Max Bayer More than six months after Akebia's anemia med was rejected by the FDA, the company is formally disputing the decision. Akebia expects a response back from regulators before the end of the year. |
Sponsored by By: Fierce Biotech Fierce Biotech sits down with biotech and drug development leaders as they discuss the latest breakthroughs and innovations driving the life sciences industry. These videos explore what's next for the biotech industry and how companies are delivering value to patients and customers in today's evolving healthcare landscape. |
By Gabrielle Masson Exelixis has made its third deal in three days, this time paying Catalent Biologics $30 million cash for licensing rights to three of its antibody-drug conjugate candidates. |
By Annalee Armstrong Abeona Therapeutics has overcome an FDA clinical hold to show that its cell therapy can heal wounds in patients with a rare connective tissue disease, teeing up an FDA filing in the new year. |
By Helen Floersh A highly targeted epilepsy gene therapy that impacts only hyperactive neurons and stops when the seizures go away showed promise in mice and human brain organoids. |
By Querida Anderson This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
By Max Bayer,Gabrielle Masson A number of Rubius executives are leaving with the company's final days numbered. Ambrx lands new CEO to chart the company through rough clinical seas. Alexion co-founder to help lead new J.P. Morgan investment venture. |
By Andrea Park For Insulet, this year has been all about the Omnipod 5 insulin pump—and that dedication is already paying off. |
By Ben Adams Move over, COVID: Shots to stop RSV are providing the new must-watch trial data on Twitter as healthcare influencers on the social media platform talk up the latest readout from Pfizer. |
By Angus Liu A patient death clouds the outlook for Eisai and Biogen's closely watched Alzheimer's disease drug lecanemab. GSK is barred from participating in China's volume-based procurement program for 18 months. Daiichi Sankyo expects AstraZeneca-partnered Enhertu to cross the blockbuster threshold in fiscal year 2022. And more. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
